DailyIQ
Last updated1 minute ago

BMY·Bristol-Myers Squibb Company

$58.66
+1.99 (+3.51%)
High
$58.66
Open
$56.81
Market Cap
116.02B
52W High
$71.00
Low
$56.58
P. Close
$58.66
P/E
12.50
52W Low
$42.52
Fwd P/E
8.55
DailyIQ Est.
$66.87
Inst. Ownership
37.3%
Short Interest
2.27%
Days to Cover
3.0
Div. Yield
4.45%
Next Ex-Div
~Jan 1
Div. Growth
18+ yrs
Technical Score (1D)
84
BULLISH
News Sentiment
57
BULLISH
On Oct 13, Bristol‑Myers Squibb announced that its investigational drug admilparant met the primary endpoint only at the lower dose tested in a phase III trial for idiopathic pulmonary fibrosis, while its drug RYZ101 achieved a significant improvement in progression‑free survival in the ACTION‑1 trial for advanced gastroenteropancreatic neuroendocrine tumors. The company also lifted its 2026 sales forecast by 5.9 % and raised its adjusted earnings‑per‑share outlook, citing a projected 20‑25 % rise in Eliquis sales before exclusivity ends in April 2028. Earlier that same day, BMY reported a 38.1 % share price increase over the past year, driven by positive late‑stage trial outcomes across cancer, cardiology and respiratory therapies, prompting investors to reassess the company’s valuation. The mixed phase III results for admilparant and the strong performance of RYZ101 were highlighted as key developments, with the former raising concerns about the drug’s dose response and the latter supporting forthcoming regulatory discussions. These events together underscored BMY’s ongoing focus on oncology and immunology, its modest FY 2025 revenue decline of 0.2 %, and its comparative stance against peers such as Eli Lilly and Pfizer.
LOW TARGET
$41 -30.1%
3 analysts
MEAN TARGET
$66 +12.2%
22 analysts
HIGH TARGET
$82 +39.8%
11 analysts
PRICE RANGE
$41.00 - $82.00
SB / B / H / S / SS
7/8/18/2/1
DAILYIQ EST.
$66.87 (+14.0%)
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYQ
Country
United States
Website
Symbol
BMY
Description
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines. Its core business centers around providing treatments for a diverse range of therapeutic areas, including oncology, hematology, immunology, and cardiovascular diseases. The company's portfolio features prominent products such as Eliquis, Opdivo, and Orencia, addressing conditions like atrial fibrillation, various cancers, and rheumatoid arthritis. Bristol-Myers Squibb distributes its biopharmaceutical products to a wide network of healthcare providers, including wholesalers, hospitals, and pharmacies, ensuring patient access to its therapies worldwide. Founded in 1887, the company maintains its headquarters in Princeton, New Jersey, and continues to evolve its product offerings to address unmet medical needs.
Bought (1Y)
0 shares
$0
Sold (1Y)
40,308 shares
$2.6M
Gallman CariEVP, General Counsel
Option Exercise4,559 shares2026-10-02
Gallman CariEVP, General Counsel
Tax Withholding2,332 shares2026-10-02
Gallman CariEVP, General Counsel
Option Exercise4,559 shares2026-10-02
YALE PHYLLIS R-
Award/Grant560.897 shares2026-09-30
Arduini Peter J-
Award/Grant560.897 shares2026-09-30
68/ 100
Bullish
Overall: Bullish
✕Revenue declining year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
71.1%
Net Margin
14.6%
Revenue CAGR
6.5%
Current Ratio
1.26x
Debt / Equity
2.43x
Return on Equity
38.2%
Earnings Summary
Bristol‑Myers Squibb is a global biopharmaceutical company that develops and markets medicines across oncology, hematology, immunology, and cardiovascular disease, with flagship products such as Eliquis, Opdivo, and Orencia. The company operates in the highly competitive drug‑manufacturing sector, where pipeline depth and regulatory approvals drive long‑term growth. In the most recent quarters, BMY posted EPS of $1.63 in Q3 2025 and $1.26 in Q4 2025, both beating analyst expectations of $1.52 and $1.13 respectively, while revenue rose to $12.22 billion and $12.50 billion, up 0.2 % year‑over‑year. The company’s Q1 2026 EPS of $1.58 also surpassed the $1.42 estimate, and revenue climbed to $11.49 billion versus the $10.92 billion forecast. In Q2 2026, EPS jumped to $2.04 against a $1.60 estimate, and revenue surged to $12.97 billion from the $11.86 billion projection, indicating a strong acceleration in both earnings and top line. Historically, BMY has maintained a steady upward trajectory in revenue, with a 0.2 % decline in FY 2025 but a rebound in subsequent quarters. The company has consistently beat EPS estimates in the last four quarters, while revenue growth has remained positive even when EPS misses have occurred in the past. This pattern underscores a resilient earnings base supported by a robust product portfolio. Recent news highlights mixed phase‑III results for the investigational drug admilparant, which met the primary endpoint only at the lower dose, and positive outcomes for RYZ101 in the ACTION‑11 trial for advanced gastroenteropancreatic neuroendocrine tumors. The company also lifted its 2026 sales forecast by 5.9 % and raised its adjusted EPS outlook, citing a projected 20‑25 % rise in Eliquis sales before exclusivity ends in 2028.

EPS

EstBeatMiss
$0.96$1.27$1.57$1.88$2.18Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.39 - -
Q2'26$1.60$2.04+27.4%
Q1'26$1.42$1.58+11.1%
Q4'25$1.13$1.26+11.9%
Q3'25$1.52$1.63+7.6%
Q2'25$1.10$1.46+32.6%

Revenue

EstBeatMiss
$10.6B$11.3B$11.9B$12.6B$13.3BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$12.7B - -
Q2'26$11.9B$13.0B+9.4%
Q1'26$10.9B$11.5B+5.2%
Q4'25$12.4B$12.5B+0.8%
Q3'25 - $12.2B -
Q2'25 - $12.3B -

Market Data

BMY Stock Snapshot

BULLISH84/100
$58.66+$1.99 (3.5%)
Market cap
116.02B
P/E ratio
12.5
Day range
$56.58 – $58.66
News sentiment
57/100 · Neutral
Analyst target
$65.83 (+12.2%)
Consensus
Hold · 36 analysts
52-week range+38.0% off low · -17.4% from high
$42.52$71.00
Price $58.66 DailyIQ Est. $66.87

Price is in the middle of its 52-week range, and the momentum read backs that positioning up. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.

Reverse DCF

What growth is priced into BMY?

CHEAP

At today's price, Bristol-Myers Squibb Company needs to grow free cash flow about -14.1% a year for the next 10 years to justify its valuation at a 6.58% cost of capital. Over its actual history it has compounded free cash flow at 10.8% a year, so the market is asking for 24.9 percentage points below its own delivered rate. On that basis BMY looks priced below what its own growth record supports.

Implied FCF growth
-14.1%
Historical FCF CAGR
10.8%
Growth gap
-24.9 pts
Verdict
CHEAP
Discount rate (WACC)
6.58%
Beta
0.53

Behaviour On Record

What BMY's own history says about today's numbers

Realized volatility (21d)
21.8% 51st pct
Below its peak
-29.2%
vs 200-day average
-3.7%
Up days (1y)
50%

Bristol-Myers Squibb Company is currently running 21.8% annualised volatility over the last 21 sessions. Measured against BMY's own 13 years of daily returns rather than a market-wide average, that is the 51st percentile — close to its own typical level, against a typical reading of 21.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

BMY is trading -29.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -24.7%, and the deepest was -36.3% in 2016. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -3.7% from its 200-day moving average. Against every other day in its history, that gap ranks at the 36th percentile — close to the gap it normally carries. Over the past year BMY closed higher on 50% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 14 years of records, BMY finished the month higher 6 of 14 times, with a median return of -2.0% and an average of +0.6%. Its strongest month historically has been February at +3.4% on average, its weakest April at -2.5%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: BMY has opened more than 2% away from the prior close in 44 of 3,268 sessions (1.3% of the time), with the largest gaps running +6.8% and -5.0%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, BMY moved an average of 2.4% in the session after earnings, closing higher 2 of those 3 times, with a median move of +0.7% and a largest of +3.8%.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against BMY's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of BMY's sector?

Bristol-Myers Squibb Company sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
91

Options Market

What is the options market pricing for BMY?

CallsPuts

For Bristol-Myers Squibb Company's nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.64), with at-the-money implied volatility around 31.4%. The options market is pricing roughly a ±2.5% move by that expiry — a range of about $57.13–$60.03.

Put/call ratio (2026-10-16)
0.64
ATM implied volatility
31.4%
Total open interest
78,090
Expected move by 2026-10-16
±2.5% ($57.13–$60.03)

Analyst Rating Changes

Are analysts turning bullish or bearish on BMY?

Wells Fargo most recently reiterated its rating on Bristol-Myers Squibb Company to Equal-Weight on Oct 13, 2026 with a price target of $60 (from $65). Over the last 90 days, coverage has run 1 upgrade against 1 downgrade, a net mixed lean.

Latest action
Wells Fargo — Equal-Weight
90-day upgrades
1
90-day downgrades
1
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 13, 2026Wells FargoMaintainedEqual-Weight$65 → $60
Oct 8, 2026Cantor FitzgeraldMaintainedNeutral$59 → $53
Oct 7, 2026Morgan StanleyMaintainedUnderweight$40 → $41
Oct 5, 2026Leerink PartnersDowngradeOutperform → Market Perform$73 → $59
Sep 16, 2026Piper SandlerReiteratedOverweight$75 → $82
Sep 10, 2026HSBCMaintainedHold$60 → $65
Aug 5, 2026Argus ResearchUpgradeHold → Buy$75
Aug 3, 2026CitigroupMaintainedNeutral$66 → $70
Jul 31, 2026RBC CapitalMaintainedSector Perform$60 → $64
Jul 31, 2026JP MorganMaintainedOverweight$67 → $73
Jul 31, 2026Cantor FitzgeraldMaintainedNeutral$54 → $59
Jul 31, 2026Wells FargoMaintainedEqual-Weight$60 → $65

Peers & ETF holders

BMY peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

57/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Bristol Myers Squibb (BMY) was highlighted as a value-oriented biopharmaceutical firm with a focus on oncology and immunology. The company reported FY 2025 revenue of $48.2 billion, a modest 0.2% decline from the prior year. A December 2025 U.S. government agreement on drug pricing and supply is already influencing BMY’s strategy for key products such as Eliquis. The article contrasts BMY’s steady performance with Eli Lilly’s recent growth momentum in weight‑loss and metabolic health. No material corporate event or guidance change was disclosed, suggesting a neutral outlook.
What did this article say?
Bristol‑Myers Squibb announced on July 30, 2026 that it would increase its 2026 sales forecast by 5.9% at the midpoint and lift its adjusted earnings per share outlook. The company cited stronger growth expectations for Eliquis, projecting a 20%‑25% rise in 2026 sales before the drug’s exclusivity ends in April 2028. In contrast, Pfizer raised its 2026 sales forecast by only 0.8% and left its earnings outlook unchanged. The BMY revision signals a more aggressive growth trajectory and a higher confidence in its product pipeline relative to its peer.
What did this article say?
Bristol Myers Squibb announced mixed phase III results for its investigational drug admilparant in idiopathic pulmonary fibrosis, meeting the primary endpoint only at the lower dose tested. The company also reported positive outcomes for RYZ101 in the ACTION-1 trial for advanced gastroenteropancreatic neuroendocrine tumors, with significant improvement in progression‑free survival. Despite the cancer trial success, the inconsistent dose response for admilparant led to a 2.6% decline in BMY shares on Oct. 12, reflecting investor unease about the drug’s clinical profile.
What did this article say?
Bristol‑Myers Squibb’s stock gained 38.1% over the past year, prompting investors to reassess its valuation relative to earnings. Recent late‑stage trial successes in cancer, cardiology, and respiratory therapies have bolstered expectations for future profitability. Analysts remain divided on whether the current share price reflects these earnings, leading to a broader discussion of BMY’s attractiveness as an undervalued stock.
What did this article say?
Bristol Myers Squibb reported positive Phase 3 data for admilparant in idiopathic pulmonary fibrosis and RYZ101 in gastroenteropancreatic neuroendocrine tumors. Admilparant demonstrated significant clinical benefits and a favorable safety profile, while RYZ101 improved progression‑free survival in its target population. These results strengthen the company’s late‑stage pipeline and set the stage for upcoming regulatory discussions, reinforcing confidence in BMY’s development trajectory.
What did this article say?
The article compares Bristol Myers Squibb (BMY) and Novo Nordisk (NVO) as potential 2026 investments, highlighting BMY’s diversified oncology and hematology portfolio against NVO’s dominance in obesity and diabetes. It notes BMY’s steeper discount valuation despite higher leverage, while NVO commands a premium due to strong profitability and GLP‑1 market leadership. Both companies face regulatory shifts, but the piece frames the comparison as a data‑driven decision for investors rather than reporting any new material event.
What did this article say?
Bristol Myers Squibb reported Phase 3 EXCALIBER‑RRMM data for its Zenbexus combination in relapsed or refractory multiple myeloma, showing significant progression‑free survival and high minimal residual disease‑negative complete response rates. The results are being used to support a potential accelerated approval for Zenbexus in this blood cancer setting, indicating a positive development for the company’s oncology pipeline.
What did this article say?
BofA Securities reduced its price target for Bristol‑Myers Squibb to $66 from $71, citing a reassessment of the company’s valuation metrics and competitive landscape. The downgrade reflects concerns over margin pressure and the impact of upcoming regulatory reviews on the drug pipeline. The move signals a more cautious outlook for the firm’s near‑term earnings potential.

Technical Analysis

Real-time indicators across multiple timeframes

84
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $42.68B combined position · 17 adding, 8 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy198,727,7689.82%$10.72B2026-01-29
BlackRock, Inc.▲ Buy180,384,9948.92%$10.39B2026-08-07
JPMorgan Chase & Co▼ Sell71,713,4423.54%$4.20B2026-08-12
Geode Capital Management, LLC▲ Buy56,443,0772.79%$3.24B2026-08-12
Norges Bank▲ Buy36,866,6581.82%$2.12B2026-08-12
Bank of America Corp▲ Buy34,045,3521.68%$1.96B2026-08-14
Morgan Stanley▼ Sell29,009,0251.43%$1.67B2026-08-13
AQR Capital Management LLC▼ Sell27,357,4861.35%$1.58B2026-08-14
Northern Trust Corp▲ Buy24,918,3841.23%$1.44B2026-08-13
Goldman Sachs Group Inc▲ Buy17,016,7990.84%$980.51M2026-08-14
FMR LLC (Fidelity)▲ Buy16,293,3030.81%$938.82M2026-08-13
Invesco Ltd.▲ Buy16,033,4800.79%$923.85M2026-08-14
Two Sigma Investments, LP▼ Sell10,085,3830.50%$581.12M2026-08-14
Wells Fargo & Company▲ Buy6,321,6430.31%$364.25M2026-08-14
AllianceBernstein L.P.▼ Sell4,757,7200.24%$288.56M2026-08-14
Man Group plc▼ Sell4,682,0000.23%$269.78M2026-08-14
Wellington Management Group LLP▼ Sell3,914,0860.19%$225.53M2026-08-14
Citigroup Inc▲ Buy3,370,1130.17%$194.19M2026-08-03
Capital World Investors▲ Buy2,244,2420.11%$129.31M2026-08-12
Prudential Financial Inc▲ Buy1,794,0300.09%$103.37M2026-08-12
Adage Capital Partners GP, L.L.C.▲ Buy1,716,0000.08%$98.88M2026-08-14
Citadel Advisors LLC▲ Buy1,572,3290.08%$90.60M2026-09-02
Neuberger Berman Group LLC▲ Buy972,8430.05%$56.06M2026-08-13
Janus Henderson Group plc▼ Sell912,9260.05%$55.37M2026-05-18
Gotham Asset Management, LLC▲ Buy892,9690.04%$51.45M2026-08-14
Q2 2026 flow:23.26M sh bought ($1.34B)27.36M sh sold ($1.60B)net -4.10M sh (−$256.30M)
Congressional Trading Activity
25 disclosed trades · ~$249.0K est. traded value · 8 buys, 17 sells
MemberChamberStateTypeAmountTradedFiled
Mike KellyHousePA16▼ Sell$15K - $50K2026-05-072026-06-11
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-12-192026-01-12
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-12-182026-01-15
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-11-132025-12-11
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-11-122025-12-15
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-08-142025-09-11
Virginia FoxxHouseNC05▼ Sell$1K - $15K2025-06-242025-07-03
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Julia LetlowHouseLA05▼ Sell$1K - $15K2025-04-282026-01-13
Tommy TubervilleSenateAL▼ Sell$1K - $15K2025-04-152026-08-05
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-04-012025-05-14
Greg LandsmanHouseOH01▼ Sell$1K - $15K2025-03-272025-04-08
Julie JohnsonHouseTX32▲ Buy$1K - $15K2025-01-152025-02-12
Valerie HoyleHouseOR04▲ Buy$1K - $15K2024-10-292025-09-12
Julia LetlowHouseLA05▲ Buy$1K - $15K2024-10-232026-01-13
Tommy TubervilleSenateAL▲ Buy$1K - $15K2024-04-032024-05-15
Tommy TubervilleSenateAL▼ Sell$1K - $15K2024-04-032024-05-15
Tommy TubervilleSenateAL▼ Sell$1K - $15K2024-01-032024-02-14
Tommy TubervilleSenateAL▼ Sell$1K - $15K2023-11-162023-12-15
Tommy TubervilleSenateAL▲ Buy$1K - $15K2023-10-172023-11-16
Dan SullivanSenateAK▼ Sell$1K - $15K2023-08-222023-09-22
Shelley Moore CapitoSenateWV▼ Sell$1K - $15K2023-05-102023-06-14
Dan SullivanSenateAK▼ Sell$1K - $15K2023-01-102023-02-13
Shelley Moore CapitoSenateWV▼ Sell$1K - $15K2022-06-172022-07-15